Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Published:2024-01 Issue:10423 Volume:403 Page:249-260
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Platzbecker Uwe,Santini Valeria,Fenaux Pierre,Sekeres Mikkael A,Savona Michael R,Madanat Yazan F,Díez-Campelo Maria,Valcárcel David,Illmer Thomas,Jonášová Anna,Bělohlávková Petra,Sherman Laurie J,Berry Tymara,Dougherty Souria,Shah Sheetal,Xia Qi,Sun Libo,Wan Ying,Huang Fei,Ikin Annat,Navada Shyamala,Feller Faye,Komrokji Rami S,Zeidan Amer M

Publisher

Elsevier BV

Subject

General Medicine

Reference37 articles.

1. Myelodysplastic syndromes;Cazzola;N Engl J Med,2020

2. Therapy for lower-risk MDS;Carraway;Hematology Am Soc Hematol Educ Program,2020

3. NCCN guidelines insights: myelodysplastic syndromes, version 3.2022;Greenberg;J Natl Compr Canc Netw,2022

4. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study;Efficace;Lancet Oncol,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telomerase inhibition in haematological neoplasms—are we ready for primetime?;The Lancet;2024-01